Early relapse for Multiple Myeloma patients undergoing single auto-SCT: A single center experience

The purpose of this study was to understand the impact of early relapse (ER) on overall survival of myeloma patients. We analyzed the outcomes of 257 patients who received novel agent based inductions and underwent single auto-SCT at our center between 2010 and 2016. We conclude that ER, high-risk cytogenetics, and LDH>350 UI/L are significant prognosticators for poor patient outcome in multiple myeloma.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research

Related Links:

Publication date: Available online 6 December 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Rafiye Ciftciler, Haluk Demiroglu, Yahya Buyukasık, Elifcan Aladag, Salih Aksu, Ibrahim C. Haznedaroglu, Nilgun Sayınalp, Osman Ozcebe, Umit Yavuz Malkan, Hakan GokerAbstractBackground and AimThe refractory acute myeloid leukemia (AML) includes patients who fail standard induction chemotherapy, relapse within 6 months after first complete remission and relapse twice or more. The outcome of these patients is usually very poor with only a small proportion could be rescued by allogenic hematopoietic stem cell transplan...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
The refractory acute myeloid leukemia (AML) includes patients who fail standard induction chemotherapy, relapse within 6 months after first complete remission and relapse twice or more. The outcome of these patients is usually very poor with only a small proportion could be rescued by allogenic hematopoietic stem cell transplantation (alloHSCT). The aim of this study is to evaluate the efficacy and feasibility of alloHSCT in patients with refractory AML.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research
•Hematologic malignancies have been reported sporadically in patients with pemphigus.•In the current study, significant associations were observed between pemphigus and chronic leukemia, multiple myeloma, and non-Hodgkin lymphoma.•Further research is needed to confirm these findings in other c ohorts.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Authors: Source Type: research
ConclusionResults of real-life studies differ from those found by prospective trials. Accordingly, early actions and supportive care are still needed, aiming to decrease toxicity, especially in developing countries.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
ConclusionThere are a number of challenges associated with the use of copanlisib. Infusion-related hypertension and hyperglycemia occur frequently, although they are transient, reversible, and rarely of clinical significance; this report provides guidance as to their management.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
ConclusionsFulminant febrile, hypotensive reactions can be seen following ABVD treatment for cHL. In the present series symptoms resolved within 24 hours with the use of intravenous corticosteroids and intensive supportive care.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 29 November 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): S. Venugopal, J. MascarenhasAbstractChronic neutrophilic leukemia (CNL) is a BCR–ABL1 negative myeloproliferative (MPN) neoplasm with notably dismal survival. The current 2016 WHO classification of myeloid neoplasms enables clinicians to unequivocally differentiate CNL from its comparable MDS/MPN overlap syndromes. Additionally, the gradual emergence of next-generation sequencing has progressively expanded our evolving understanding of the molecular pathogenesis of CNL and its therapeutic potential. Hematopoiet...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Copanlisib, an intravenously administered agent with inhibitory activity that predominantly targets the alpha and delta isoforms of PI3K, was granted accelerated approval by the US Food and Drug Administration on the basis of its activity in the third-line treatment of follicular NHL. Copanlisib is associated with several potentially serious adverse conditions, some of which are not shared with other PI3K inhibitors (i.e. infusion-related hyperglycemia and hypertension). Education and guidance are needed to help physicians manage adverse effects associated with copanlisib treatment. Therefore, this panel developed recommen...
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) is a widely used frontline regimen for the treatment of early and advanced stage classical Hodgkin ’s lymphoma (cHL). A fulminant syndrome characterized by pyrexia and shock was observed in early trials of bleomycin, occurring more frequently in patients with lymphoma. In the past three decades, only one case of a similar fulminant reaction following ABVD has been reported and thus there is lim ited literature regarding the risk factors, clinical course, and management for this life threatening syndrome.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Case Report Source Type: research
Chronic neutrophilic leukemia (CNL) is a BCR –ABL1 negative myeloproliferative (MPN) neoplasm with notably dismal survival. The current 2016 WHO classification of myeloid neoplasms enables clinicians to unequivocally differentiate CNL from its comparable MDS/MPN overlap syndromes. Additionally, the gradual emergence of next-generation sequen cing has progressively expanded our evolving understanding of the molecular pathogenesis of CNL and its therapeutic potential. Hematopoietic stem cell transplantation (HSCT) remains the primary therapeutic option for the effective treatment of CNL.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Review Article Source Type: research
More News: Hematology | Leukemia | Lymphoma | Myeloma | Study